Skip to main content

03.01.2019 | Laboratory Investigation | Ausgabe 1/2019

Journal of Neuro-Oncology 1/2019

PPAR and GST polymorphisms may predict changes in intellectual functioning in medulloblastoma survivors

Journal of Neuro-Oncology > Ausgabe 1/2019
Adeoye Oyefiade, Lauren Erdman, Anna Goldenberg, David Malkin, Eric Bouffet, Michael D. Taylor, Vijay Ramaswamy, Nadia Scantlebury, Nicole Law, Donald J. Mabbott
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1007/​s11060-018-03083-x) contains supplementary material, which is available to authorized users.



Advances in the treatment of pediatric medulloblastoma have led to improved survival rates, though treatment-related toxicity leaves children with significant long-term deficits. There is significant variability in the cognitive outcome of medulloblastoma survivors, and it has been suggested that this variability may be attributable to genetic factors. The aim of this study was to explore the contributions of single nucleotide polymorphisms (SNPs) in two genes, peroxisome proliferator activated receptor (PPAR) and glutathione-S-transferase (GST), to changes in general intellectual functioning in medulloblastoma survivors.


Patients (n = 44, meanage = 6.71 years, 61.3% males) were selected on the basis of available tissue samples and neurocognitive measures. Patients received surgical tumor resection, craniospinal radiation, radiation boost to the tumor site, and multiagent chemotherapy. Genotyping analyses were completed using the Illumina Human Omni2.5 BeadChip, and 41 single nucleotide polymorphisms (SNPs) were assessed across both genes. We used a machine learning algorithm to identify polymorphisms that were significantly associated with declines in general intellectual functioning following treatment for medulloblastoma.


We identified age at diagnosis, radiation therapy, chemotherapy, and eight SNPs associated with PPARs as predictors of general intellectual functioning. Of the eight SNPs identified, PPARα (rs6008197), PPARγ (rs13306747), and PPARδ (rs3734254) were most significantly associated with long-term changes in general intellectual functioning in medulloblastoma survivors.


PPAR polymorphisms may predict intellectual outcome changes in children treated for medulloblastoma. Importantly, emerging evidence suggests that PPAR agonists may provide an opportunity to minimize the effects of treatment-related cognitive sequelae in these children.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Supplementary material 1 Supplementary fig 1. Density plot of VIMP scores for variables with scores less than or equal to zero across all iterations of the prediction RFR model. Due to space considerations axes labels have been omitted. The dashed red line indicates a vimp score of zero. Values to the left of the dashed line indicate negative vimp scores. Supplementary fig 2. Boxplots showing the relationships between intellectual outcome and age at diagnosis, radiation therapy, and chemotherapy. Intellectual outcome was determined as the predicted change in FSIQ scores over time based on RFR model estimates. Older age at diagnosis predicted better intellectual outcome, while reduced craniospinal radiation with a tumor bed boost, as well as the SJMB03 chemotherapy protocol predicted better intellectual outcome. Radiation therapy: S-PF – Standard dose + posterior fossa boost, S-TB – Standard dose + tumor bed boost, R-PF – Reduced dose + posterior fossa boost, R-TB – Reduced dose + tumor bed boost. Chemotherapy protocols: CCCG 9961 (Vincristine, Lomustine, Cisplatin); POG 9631 (Etoposide, Cisplatin, Cyclophosphamide, Vincristine); SJMB03 (Vincristine, Cisplatin, Cyclophosphamide, Amifostine); 99703 (Vincristine, Cisplatin, Cyclophosphamide, Etoposide); ACNS 0331 (Lomustine, Cisplatin, Vincristine, Cyclophosphamide) (TIF 244 KB)
Supplementary material 2 (TIF 225 KB)
Supplementary material 3 (DOCX 17 KB)
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2019

Journal of Neuro-Oncology 1/2019 Zur Ausgabe
  1. Sie können e.Med Neurologie & Psychiatrie 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Sie können e.Med Neurologie 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  3. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.